Wave Life Sciences Tech Stack
RNA therapeutics platform for rare and common genetic diseases
Wave Life Sciences is a public biotech company developing RNA medicines across four clinical programs (Alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy, Huntington's disease, obesity) using their PRISM platform. The hiring pattern—dominated by healthcare and ops roles at senior/director levels, with active recruitment in US and UK—reflects a company scaling clinical operations and manufacturing infrastructure rather than early-stage discovery; paired with projects spanning cold chain management, GLP/GCP compliance, and technology transfer, this signals a shift from lab-stage development toward clinical execution and commercial readiness.
Tech Stack 22 technologies
What Wave Life Sciences Is Building
◆Challenges
- Scalability of large bioinformatics datasets
- Uninterrupted site supply
- Improving financial processes and systems
- Compliance with gcp gvp glp regulations
- Continuous improvement of clinical quality practices
- Risk management in clinical operations
- Equipment maintenance delays
- High-performance compute environments
- Ensuring compliance to gdps and sops
- Resolving equipment and process issues
▲Active Projects
- Clinical development of cardiometabolic programs
- Sequence-based machine learning projects
- Cold chain management
- Pipeline development for mapping coordinates and homology of oligonucleotides
- Design of clinical development programs for investigational products
- Glp/gcp quality strategy implementation
- Development of oligonucleotide therapeutics tools
- Clinical quality risk management strategy
- Clinical trials
- Technology transfer
Hiring Activity
Department
Seniority
Notable leadership hires: Field Medical Lead